Kelun Pharmaceutical

Sichuan Kelun Pharmaceutical is a leading Chinese pharmaceutical conglomerate that has successfully transitioned from a dominant player in the intravenous infusion market to a global innovator in oncology. The company operates a massive manufacturing infrastructure for generics and parenteral nutrition while driving cutting-edge R&D through its subsidiary, Kelun-Biotech. Kelun is best known internationally for its sophisticated antibody-drug conjugate (ADC) platform, which led to a landmark multi-billion dollar collaboration with Merck & Co. (MSD). Its pipeline includes several late-stage candidates targeting TROP2 and HER2, positioning the company as a significant competitor in the global biologics landscape. With a presence spanning from traditional chemical drugs to advanced immunotherapy, Kelun remains a cornerstone of the Chinese healthcare industry.